0001493152-22-023263.txt : 20220817 0001493152-22-023263.hdr.sgml : 20220817 20220816190354 ACCESSION NUMBER: 0001493152-22-023263 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220815 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220817 DATE AS OF CHANGE: 20220816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40761 FILM NUMBER: 221171680 BUSINESS ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 832-1626 MAIL ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 8-K 1 form8-k.htm
0001630113 false 0001630113 2022-08-15 2022-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): August 15, 2022

 

BIOTRICITY INC.

 

(Exact name of registrant as specified in its charter)

 

Nevada   001-40761   30-0983531

(State or Other Jurisdiction of  

Incorporation or Organization)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

203 Redwood Parkway, Suite 600
Redwood City, California 94065

 

(Address of Principal Executive Offices)

 

(650) 832-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BTCY   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition

 

On August 15, 2022, Biotricity, Inc. (the “Company”) issued a press release reporting certain unaudited financial results for its fiscal 2023 first quarter ended June 30, 2022. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall any of them be incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits. The exhibit listed in the following Exhibit Index is furnished as part of this Current Report on Form 8-K:

 

Exhibit Number   Description
99.1   Press Release dated August 15, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: August 16, 2022

 

  BIOTRICITY INC.
     
  By: /s/ John Ayanoglou
    John Ayanoglou
    Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Biotricity Reports Financial Results for Fiscal 2023 First Quarter 

 

REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.

 

Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks.”

 

Q1-FY23 Financial Highlights:

 

  ● Revenue totaled $2.1 million.
  ● Gross profit totaled $1.2 million.
  ● Gross profit margins were 60% and consistent with the full year FY22.
  ● Net loss totaled $5 million or $0.098 per share; adjusted loss per share, a non- GAAP measure, was $0.085 per share after removing certain non-recurring expenses.

 

 

 

 

Operating Highlights for the FY22 to Date:

 

●After receiving FDA 510(k) clearance in January 2022, in April 2022, Biotricity officially launched wireless wearable holter patch device, Biotres, a revolutionary holter technology.
●Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem.
●Launched Bioheart, one of the first heart rhythm recorders and personal heart lifestyle solutions.
●Expanded our network to cover 29 states with over 2,000 physicians using our product.

 

Full details of the Company’s financial results will be filed with the SEC on Form 10-Q by visiting www.sec.gov.

 

Financial Results Conference Call

 

Management will host a conference call on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://www.biotricity.com/investors/

 

Event: Biotricity Fiscal First Quarter 2023 Financial Results Conference Call
Date: Monday, August 15, 2022
Time: 4:30 p.m. Eastern Time
Live Call: 1-888-220-8451 (U.S. Toll-Free) or 1-646-828-8193 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1561778&tp_key=c6d6c779d3

 

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 29, 2022 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 2688378.

 

 

 

 

About Biotricity:

 

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

 

Important Cautions Regarding Forward Looking Statements:

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

 

 

 

 

Use of Non-GAAP Information

 

In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP in this press release, Biotricity presents adjusted net loss, which is a non-GAAP financial measure. Adjusted net loss is determined by deducting one-time derivative fair value and accretion expenses from net loss attributable to common shareholders. Our definition of adjusted net loss may not be comparable to the definitions of similarly titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of its reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company’s internal reporting to evaluate its operations and the performance of senior management.

 

The following reconciliation calculates the adjusted loss per share:

 

  

3 months
ended
June 30,

2022

   $
Net loss attributable to common stockholders   (5,024,389)
Add:     
Provision for income taxes   -   
Interest expense   388,388 
Depreciation expense   1,488 
EBITDA   (4,634,512)
      
Add (Less)     
Other (income) expense related to convertible note conversion   50,908 
Fair value change on derivative liabilities   198,224 
      
Adjusted EBITDA   (4,385,381)
      
Weighted average number of common shares outstanding   51,440,944 
Adjusted Loss per Share, Basic and Diluted   (0.085)

 

Contacts:

 

Investor Relations:

KCSA Strategic Communications

Valter Pinto or Jack Perkins

(212) 896-1254

investors@biotricity.com

 

Media Relations:

 

Erica Fiorini, Russo Partners

(212) 845-4253

Erica.Fiorini@russopartnersllc.com

 

 

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS AT JUNE 30, 2022 (unaudited) AND MARCH 31, 2022 (audited)

(Expressed in US Dollars)

 

   As at June
30, 2022		   As at March
31, 2022		 
    $    $ 
CURRENT ASSETS          
Cash   7,207,974    12,066,929 
Accounts receivable, net   1,826,920    2,006,678 
Inventory   1,431,054    842,924 
Deposits and other receivables   380,592    406,280 
Total current assets   10,846,540    15,322,811 
Deposits   85,000    85,000 
Long-term accounts receivable   -    - 
Property and equipment   25,970    27,459 
Operating right-of-use lease asset [Note 10]   1,192,169    1,242,700 
TOTAL ASSETS   12,149,679    16,677,970 
           
CURRENT LIABILITIES          
Accounts payable and accrued liabilities [Note 4]   2,701,077    2,595,747 
Convertible promissory notes and short term loans [Note 5]   1,238,000    1,540,000 
Derivative liabilities [Note 8]   419,332    520,747 
Operating lease liability [Note 10]   219,033    210,320 
Total current liabilities   4,577,442    4,866,814 
           
Federally guaranteed loans [Note 7]   870,800    870,800 
Term loan [Note 6]   11,662,742    11,612,672 
Derivative liabilities [Note 8]   537,318    352,402 
Operating lease liability [Note 10]   1,061,795    1,120,018 
TOTAL LIABILITIES   18,710,097    18,822,706 
           
STOCKHOLDERS’ EQUITY (DEFICIENCY)          
Preferred stock, $0.001 par value, 10,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 1 share issued and outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9]   1    1 
Preferred stock, $0.001 par value, 20,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 6,872 and 7,201 preferred shares issued and outstanding as at June 30, 2022 and as at March 31, 2022, respectively [Note 9]   8    7 
Preferred stock   1    1 
Common stock, $0.001 par value, 125,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively. Issued and outstanding common shares: 50,219,034 and 49,810,322 as at June 30, 2022 and March 31, 2022, respectively, and exchangeable shares of 1,466,718 and 1,466,718 outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9]   51,685    51,277 
Shares to be issued 95,515 and 123,817 shares of common stock as at June 30, 2022 and March 31, 2022, respectively) [Note 9]   72,299    102,299 
Additional paid-in-capital   91,912,772    91,507,478 
Accumulated other comprehensive loss   (535,653)   (768,656)
Accumulated deficit   (98,061,531)   (93,037,142)
Total stockholders’ equity (deficiency)   (6,560,418)   (2,144,736)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY   12,149,679    16,677,970 

 

 

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE MONTHS ENDED JUNE 31, 2022 AND 2021 (unaudited)

(Expressed in US Dollars)

 

   3 Months
Ended
June 30,
2022		   3 Months
Ended
June 30,
2021		 
    $    $ 
REVENUE   2,056,052    1,764,110 
Cost of Revenue   830,923    525,426 
GROSS PROFIT   1,225,129    1,238,684 
EXPENSES          
General and administrative expenses [Notes 8, 9 and 10]   4,881,003    3,652,203 
Research and development expenses   821,176    588,997 
TOTAL OPERATING EXPENSES   5,702,179    4,241,200 
Other (income)/expense [Note 8] [Note 9]   -    (8,782)
Loss upon convertible promissory notes conversion   50,908    28,215 
Accretion and amortization expenses [Note 5] [Note 6]   50,070    2,335,167 
Change in fair value of derivative liabilities [Note 8]   198,224    298,983 
NET LOSS BEFORE INCOME TAXES   (4,776,252)   (5,656,099)
Income taxes   -    - 
NET LOSS BEFORE DIVIDENDS   (4,776,252)   (5,656,099)
Less: Preferred Stock Dividends   248,137    241,264 
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS   (5,024,389)   5,897,363 
Translation adjustment   233,003    6,560 
           
COMPREHENSIVE LOSS   (4,791,386)   (5,890,803)
           
LOSS PER SHARE, BASIC AND DILUTED   (0.098)   (0.151)
           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING   51,440,944    39,095,637 

 

 

 

 

BIOTRICITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)

(Expressed in US Dollars)

 

   Three
Months
Ended June
30, 2022		   Three
Months
Ended June
30, 2021		 
   $   $ 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss   (4,776,252)   (5,656,099)
Adjustments to reconcile net loss to net cash used in operations          
Stock based compensation   149,190    155,851 
Issuance of shares for services   7,051    - 
Issuance of warrants for services   77,414    151,897 
Accretion and amortization expenses   -    2,335,167 
Change in fair value of derivative liabilities   198,224    298,983 
Loss on debt   50,908    28,213 
Property, plant and equipment depreciation   1,488    - 
Changes in operating assets and liabilities:          
Accounts receivable, net   179,758    (401,818)
Inventory   (588,130)   92,694 
Deposits and other receivables   (4,312)   (86,221)
Accounts payable and accrued liabilities   416,047    399,937 
Net cash used in operating activities   (4,288,164)   (2,681,396)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
property, plant and equipment   -    - 
Net cash used in investing activities   -    - 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Issuance of common shares, net   -    - 
Issuance of preferred shares, net   -    - 
Redemption of preferred shares   (328,904)   - 
Exercise of warrants for cash   -    146,250 
Federally guaranteed loans   -    499,900 
Proceeds from (repayment to) convertible notes, net   -    - 
Proceeds from (repayment to) convertible debentures, net   -    139,780 
Issuance of shares from uplisting   -    - 
Proceeds pursuant to term loan, net   50,070    - 
Preferred Stock Dividend   (516,817)   (204,842)
Net cash provided by financing activities   (795,651)   581,088 
           
Effect of foreign currency translation   224,860    100,334 
Net increase (decrease) in cash during the period   (5,083,815)   (1,999,974)
Cash, beginning of period   12,066,929    2,201,562 
Cash, end of period   7,207,974    201,588 

 

 

 EX-101.SCH 3 btcy-20220815.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 btcy-20220815_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 btcy-20220815_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Aug. 15, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 15, 2022
Entity File Number 001-40761
Entity Registrant Name BIOTRICITY INC.
Entity Central Index Key 0001630113
Entity Tax Identification Number 30-0983531
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 203 Redwood Parkway
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 832-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol BTCY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001630113 2022-08-15 2022-08-15 iso4217:USD shares iso4217:USD shares 0001630113 false 8-K 2022-08-15 BIOTRICITY INC. NV 001-40761 30-0983531 203 Redwood Parkway Suite 600 Redwood City CA 94065 (650) 832-1626 false false false false Common Stock, par value $0.001 per share BTCY NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biotricity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm btcy-20220815.xsd btcy-20220815_lab.xml btcy-20220815_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "btcy-20220815_lab.xml" ] }, "presentationLink": { "local": [ "btcy-20220815_pre.xml" ] }, "schema": { "local": [ "btcy-20220815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "BTCY", "nsuri": "http://biotricity.com/20220815", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-08-15to2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biotricity.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-08-15to2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-023263-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-023263-xbrl.zip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�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end